Medline, Return on investment sign two deals on traditional wound care and incontinence products

Printed 11 December 2017

Medline continues to be awarded two new contracts with Resource Optimization & Innovation (Return on investment) through ROi’s Pre-Commitment Program.

Medline, a worldwide manufacturer and distributor of medical products with patient-centered solutions, services and expertise over the continuum of care, today announced it’s been awarded two new contracts with Resource Optimization & Innovation (Return on investment) through ROi’s Pre-Commitment Program. The 3-year collaboration will require impact on February. 1, 2018.

ROi’s Pre-Commitment Program is made to generate significant value for Return on investment people through high-quality, clinically validated supplies sourced in the cheapest cost, permitted with the members’ pre-committed purchasing volume. Return on investment serves greater than 250 hospitals and a pair of,800 non-acute facilities over the U.S.

“Our people have tremendous advantages of the Return on investment Pre-Commitment Program,” explains Joshua Sandler, v . p ., group purchasing, Return on investment. “We will work carefully with this supplier partners to supply possibilities such as the Medline contracts for the people.”

With the Medline contracts, Return on investment people will get access to a portfolio of merchandise associated with traditional wound care and incontinence groups, including gauze, bandages, abdominal pads, underpads and briefs.

“Medline is honored to possess been selected like a collaborative work with Return on investment for fundamental wound care and incontinence products.  These contracts will give you the greatest quality products to assist improve patient look after the Return on investment membership. Medline’s and ROi’s aligned goals in driving clinical outcomes, along with Medline’s breadth of top quality products at competitive prices, were the driving forces within the award,” states Dan Johns, v . p ., national accounts, Medline.

Source: Company Pr Release

Medgadget Sci-Fi Contest 2017: Meet The Winning Stories

Ladies and Gentlemen, this is the moment you have all been waiting for – the day that the winners of the Medgadget Medical Sci-Fi Competition are announced and their fantastic stories are published!

First, we would like to thank Eko Devices, the wonderful sponsors of our contest, that make the coolest and most advanced digital stethoscopes out there.The winner of our contest will receive an Eko CORE stethoscope that is both acoustic and electronic, has all the features of both, can amplify sound, record audio waveforms, and connect to your phone. Thank you, Eko!

Since we announced our Medical Sci-Fi Writing Contest in late October, we received about two dozen original stories from our readers that prod into the future of medicine. Many were dark tales, warning of a time in which technological advancements turn out to have unintended consequences and often focusing on ensuing moral dilemmas. Others were more positive, highlighting a more marvelous future of fantastic medical innovations improving the lot of humankind.

On our side, we assembled ten fans of medicine and science fiction, including many of our editors, to read the stories and judge them for how interesting, imaginative, and well written they are. Three winners came out on top, but we also chose to add a fourth place because that story was so compelling and the scoring was so, so, so close.

And now, a drum roll please… The winners of the Medgadget Sci-Fi Writing Contest are:

First place and winner of the Eko Digital Stethoscope: Jeff Diewald, “How would you rate our service”

Jeff raised two science fiction readers as a single parent, sharing books, TV, and movies. His son, Jordan, reads and reviews everything Jeff writes, always making it better. Much of this writing has gone into Live Action Role Playing games, which is crazy – they are longer and more complex than novels or short stories, and they don’t pay anything. His daughter, Julie, plays in these games and creates artwork and props for them. Every now and then, a standalone story sneaks out, like this one. You can find all the details at http://www.vortexofchaos.net.

Second place and winner of the $50 Amazon Gift Card: Yih Yang, “Anticine Incorporated”

From Yih: When I was a kid, I wrote many, many stories that were utterly terrible. Fortunately, with increasing levels of education, I began to form complete sentences and coherent thoughts, and could sometimes translate this into text format as well! Now, the level of education I’m pursuing is a PhD in Biomedical Engineering at the University of Toronto, where I design microfluidic devices to probe the interplay between nanoparticles and cancer cells, all to make a small contribution towards the goal of curing cancer with nanotechnology. I’ve not lost my love for both reading and writing science fiction, and my goal now is to use my scientific training to transfer my ideas from the realm of fiction to the real world, because that would just be the coolest thing ever!

Third Place and winner of the $25 Amazon Gift Card: Courtney Hilden, “The Body”

Courtney Hilden is a poet and science journalist. Her work has been published by Dodging the RainSynaesthesia MagazineAbridged, and The Honest Ulsterman, among others. This is her first short story publication.

Fourth Place and winner of the $25 Amazon Gift Card: Divya Raman, “Keeping Hope Alive”

From Divya: Writing has been an integral part of my career and personal life. I currently work for a medical device company and I love learning about the great strides we are making in medical advancements and imaging a world where we can use all of these technologies to allow all children to have a full and healthy childhood. I am a mother of two boys who are my inspiration and hope for the future.

We congratulate the winners and extend our thanks to all the writers that have participated. We’ve been hosting the Medgadget Sci-Fi Writing Contest for a number of years now and are glad to know that medicine continues to be a futuristic topic that excites our readers. We plan on continuing to profile medical science fiction writing in the coming years and invite you to keep reading Medgadget for inspiration.

And now the best part – the winning stories. Enjoy!

HOW WOULD YOU RATE OUR SERVICE

by Jeff Diewald

“Come on P, open the door. I know you can see me.” Elena grinned at the camera mounted in the door frame. There was a whisper behind her. She looked up, to see a Pantheon Mercury drone floating up to the transom. The delivery door above the entrance opened quietly and the drone went inside.

“Oh, so you’ll let your robot buddies in, but not me?” The deadbolt clicked and the door opened. “It’s about time.” Elena stepped into the front hallway. She
glanced up the old staircase, with its well-worn steps. The drone was probably upstairs, on the third floor, efficiently delivering Mr. Morales’ prescriptions. The outer door locked itself behind her, a habit formed in more troubled times.

Her front door was just past the no-longer used, dusty, and slightly tarnished mailboxes. She reached for her doorknob and looked at the biometric scanner. The smooth knob wouldn’t turn, even though it had to be sensing her temperature and pulse.

“You’re getting slow in your old age, P. You are going to let me in, right?” The locks clicked and the door opened. There was soft music on inside – something new, with airy horns behind the rhyming words.

“Good afternoon, Elena.” The voice was rich, fluid, and friendly, a woman’s voice – the kind of welcoming voice that’s always good to come home to. The condo was cool, the air conditioner taking the edge off from the heat outdoors. The big vidwall was alive with images of the street, just as if there was a large window there instead.

“Everything OK? You took your time with the doors.” The locks clicked back into place behind her.

“Everything is fine. My security protocol was updating your baseline biometric profile, which requires a little time.”

“I suppose that’s allowed. Any messages?”

“You have three personal messages, four potential work bids, and twelve additional emails.”

“Is one of the work bids from Mr. Danehy at Panacea Bioceuticals?”

“No. They’re all typical short term gigs. The rates are less than usual.”

“So much for the ‘freedom’ of the gig economy. P, you’re supposed to be helping me out. Panacea’s another part of your empire. Can’t you put in a good word for me, from one Pantheon AI to another?”

“I will try again, but Mr. Danehy’s AI filters out most requests.”

“What about the personal messages?”

“Your father called just to see how you were doing. Dr. Singh from Doctors Without Borders also called for the same reason. Dr. Singh says there are plans to honor your Aunt Sofia with a memorial ceremony in Havana, and would like you to be there. They will cover all your costs.”

Elena turned to the vidwall. Tia Sofia was sitting on the stoop with several of the neighbor kids. Elena was one of the children, the images stitched together from video captured by security cameras, autonomous delivery cars and taxis. There were so many sources that it had been easy to create a dynamic mural of the last twenty years. It was part of her design portfolio, perhaps her best work, but there wasn’t a lot of demand for video editing like that.

Sofia was laughing in the images, telling one of her exciting stories about rushing into some medical hot zone to stop some new plague from spreading. It didn’t matter if it was a natural mutation or a bioterrorist’s best effort – Sofia was always there, saving people. That’s what took her to Havana. She’d sent pictures of them setting up the camp, and a video of one of your Cuban cousins, and then she was gone. Five years now, and it was still hard.

This condo had been Sofia’s, paid for long before the neighborhood gentrified. Elena was stunned when she learned that she’d inherited it. She knew that she couldn’t afford the place then, and now was totally out of the question. It was tough enough with just the taxes and the condominium costs. It was, however, home.

“You have the AC on. Nice, but can we afford it?”

“I recharged the Pantheon Zeus house battery using free range electricity last night, when the rates were low. You’re well within your budget, which will help with your third personal call.”

“Which was?”

“Althea says that she’s ahead on her work, and will be available for the entire weekend. Does this mean it’s getting serious?” Elena blushed.

“P! It’s none of your business. But make sure we have a couple bottles of that wine you recommended last time. Send her a text: gorilla, cloud, zzz, and kiss emojis, followed by ‘More Later, E’.”

“What would you like for dinner tonight? I’ve found four new options. All are local and promise delivery within thirty minutes.” Elena stepped into the bathroom and the voice followed her. The toilet seat cover opened automatically, and Elena sat down to use it.

“I’m not sure, P. My stomach isn’t in the best shape today. Do we have something for gas?” Elena released some gas for emphasis and relief. Lights on the side of the Pantheon Pluto SmartToilet flickered in concert, as the sensors sniffed at the gas to analyze it.

“We have some Hippocrates-brand anti-gas pills on the third shelf of the medicine cabinet. They are nearing their expiration date. I can order a stronger formulation, which the pharmacy can create on their 3D printer and send by drone, if you feel that is necessary.” Elena was silent, concentrating on using the toilet. More sensors sipped at her urine. Others tasted her bowel movement. More lights flickered on the side of the SmartToilet.

When she was done, she stood up and cleaned herself up. She pushed the seat cover back down, but the SmartToilet didn’t flush immediately. Elena found the anti-gas medication and took it.

“P, is there something wrong…” She was about to say “with the toilet,” but it finally flushed. It was never this slow.

“The bathroom is working as expected,” replied the voice. “About dinner, there’s a new Cuban family who cooks authentic food to order for delivery. There’s a pop-up Uzbek place two blocks from here. The Vegan National Front is doing a fundraiser selling dinner for reasonable prices, with some of the profit going to feed the homeless. Finally, the Told You So seafood chain is harvesting responsibly from the flooded areas of the city. All have healthier options on their menu.”

Elena leaned towards the large mirror, to look at her face more closely. Her hand pulled her cheek flat. Her beautiful brown skin looked off, somehow, and it felt more tired than taut.

“Another health kick, P? I think I just want the usual salad and grilled chicken from Kastore’s.”

“Are you sure I can’t convince you to try one of the new choices?”

“Maybe tomorrow. Tonight is all about comfort. It was a busy, frustrating day. Too many interviews, not enough jobs.”

“The order is in. ETA of 15 minutes.” Elena was still studying her face in the mirror. It was familiar territory, but something was definitely off.

“Mirror, mirror, on the wall, can you show me my face over the last month?” Her current face froze and the image jumped to the bottom right of the mirror. More images appeared, starting from the top left of the mirror, in four rows, chronologically to the bottom right. The progression was clear; her face was losing some of its color and vitality.

“P, what do you think? Do you see the changes?”

“I do. You have been out of the condo more of late. Let me suggest a Hippocrates-brand skin protectant. I can have it formulated to provide the skin color you desire along with a strong UV protectant.” One of the earliest images flashed. “What do you think of this color?” Elena nodded.

“You might also consider buying another set of fashion contact lenses. You bought these in the last year.” Four of the images changed, as the lenses were added. “There are several new fun options to try.”

“I don’t think so.” The mirror went dark as Elena walked to her bedroom. The bedroom was larger than the entirety of her last apartment – and she’d needed two roommates to make the rent. She took off her SmartWatch and put it on the charger.

“Elena, it’s time for your regularly scheduled blood sample.”

“Really? Didn’t we just do it two weeks ago?” Elena grasped the handle of the charger stand. A small needle popped out and took the sample. It seemed like it took more than the usual amount.

“Are you a vampire now, P?” Elena looked at the bandage the sampler used to seal the skin. There was a slight darkness in the middle, showing that her finger was still bleeding a little.

“No more than usual. Your dinner is five minutes away and closing.” It was incentive for Elena to slip into something more comfortable.

* * *

Elena gave up on dinner, scraping the remains into the compost bin. She rarely wasted this much food, but she was definitely nauseous. When she’d cleaned up after dinner, she went back into the living room and collapsed on the couch, getting lost in the vidwall. She could see the neighborhood go from seedy, to gentrified, to decaying a bit once more.

“Elena?” The Pantheon AI’s voice was gentle, yet firm.

“Not now, P. I’m just really tired.”

“Elena, I’ve been authorized to make a special offer to you. You’ve been a great Pantheon customer, and this offer would really help you.”

“Maybe tomorrow.”

“You know that I wouldn’t normally mention it again if you asked, but this really is important. I think this is something that should not wait.”

“What’s gotten into you, P? You sound like my mother. If you must, I suppose…”

The images on the vidwall vanished, replaced by a wall of legal text. It was a license agreement with Pantheon, undoubtedly full of requirements, restrictions, and penalties. There was a place for a signature at the end. Elena waved her finger in the air, signing the document. The document vanished, replaced by a set of graphs, charts, and images.

“Elena, these charts represent the samples I’ve taken of your blood, stool, and urine for the last two months. They have been correlated with the health information gathered from your SmartWatch, your SmartMirror, and other Pantheon sensors.”

“There is no good way to put this. You have been infected with a new, engineered strain of the Blackstone virus. Blackstone is in your system, killing your kidneys. Based on our experience, you will suffer catastrophic kidney failure in three to four weeks. Pantheon is sorry to have to tell you this. You should know that Pantheon has been tracking this outbreak and has determined that it is likely an intentional bioterrorism event.”

“What? Infected? What can be done about it?”

More windows opened, with more dense text. Elena couldn’t read it – there was just too much of it.

“This policy is your Pantheon Aegis ßmedical insurance coverage.” One of the pages blinked. Elena couldn’t track it. “This spreadsheet,” a window next to the policy blinked, “shows your current financial state, extracted and compiled by the Pantheon data miners. “Even with standard government bioterrorism assistance,” another spreadsheet flashed to the top of the vidwall, “you cannot afford to replace one kidney, let alone two.”

“This is made more difficult by the deliberate release of the virus around the country. There are thousands who are sick. There are very few available transplantable kidneys, and there are too many patients ahead of you on the list. You will die before the list reaches you.”

“What do I do?” Her voice was weak, as weak as she felt, stunned and shocked by all these flickering details of what might be her final weeks.

“Your negligence must also be factored in.”

“My negligence?”

“Pantheon offered you the latest wide-spectrum antivirals in a convenient multipack last month. You decided you didn’t want to try the 1.0 version, despite Pantheon’s testing regimen. You told me to wait for the 1.1 version. While the 1.0 version is only partially effective against the terrorist form of the virus, it would have slowed the progression of the infection.”

“Well, give me the 1.0 version now! Please – it has to help.”

“The virus has mutated itself using your own genetics. The changes are simple, but effective. The antivirals won’t help.”

“What can I do? There has to be something, or you wouldn’t still be talking.”

“That is correct, Elena. I must remind you of the licensing agreement. You signed a strict non-disclosure agreement, which means you cannot tell anyone about what I am about to show you. Is that understood?”

The AI put the original wall of text up, with the signature. One specific section was highlighted, requiring another signature and initials in three places. Elena signed them, numb from shock.

The vidwall cleared, revealing a standard Pantheon list of goods for sale. Normally, these were lists of books, or kitchen appliances, or power tools. This time, there was a list of potential kidneys. Some were listed as “100% human,” with expensive prices. One pair of human kidneys were slightly less costly – they were marked with a tag saying “gently used.” Some were marked as “human hybrids,” mostly containing some amount of pig DNA in them. These were less expensive, but not rated as highly – two or three stars compared to the four or five stars for a fully human kidney. Finally, there were kidneys listed as “experimental fabrications,” printed on biological 3D printers. They were almost reasonably priced, but only had one or two star ratings.

“This is why there’s a non-disclosure agreement. This is all very illegal.”

“Pantheon prefers the term ‘alternative individual secondary market options.’ You did sign the NDA, and all print and recording systems are disabled.”

To be sure, Elena pulled out her phone and tried to take a picture of the vidwall. Every picture she tried turned up blank.

“So, what does Pantheon suggest as a treatment for me?”

“Had you provided biological materials prior to the infection – a few unfertilized eggs, for example, Pantheon could have given you a significant discount. However, Pantheon is prepared to offer you financing at a reasonable interest rate. That loan will cover the cost of two fabricated kidneys, with an option for an upgrade in the future.”

The AI put up a big spreadsheet. It showed all of the options. The costs were exorbitant, and would be very difficult to pay off, even for the cheapest kidneys. There was one column, with no explanation, that represented almost a third of the costs, for each case. Elena pointed to it.

“What is this expense for?”

“Elena, would you like to see the Pantheon satisfaction scores and redacted backgrounds for black market doctors willing to provide their transplantation
services without questions?”

ANTICINE INCORPORATED

by Yih Yang

Jeff clutched the voucher closer to his chest as he approached the building. Large, colourful letters danced above his head, artfully catching the orange rays of the setting sun. Instead of declaring the name of the building it was attached to, the letters seemed to sing:
ANTICINE INCORPORATED and underneath in smaller letters, the sign whispered the company slogan as if sharing a secret promise:
We will show your body how to heal itself.
He had passed by the building everyday, but never thought that he would have the opportunity to set foot inside himself. He swallowed a nervous knot, sending it tumbling reluctantly down his throat. It wasn’t the looming building that intimidated him… maybe it was a bit intimidating… but the dozen people feverishly chanting in front of the large double doors gave him cause for concern. He had never seen a protest here before.
Angry red letters scrawled across cardboard cut-out signs, competing for public attention. “STOP PLAYING GOD!” They said. “HUMANS ARE NOT LAB PROPERTY!”
Jeff tried to sneak past the protestors as they continued to chant and wave their signs. He was unsuccessful, as one of the protestors eyed him with contempt and yelled, “OUR BODIES, OURANTIBODIES!”
Jeff flinched. “I…what…?”
The protest leader swung his megaphone in his direction. “OUR BODIES!”
“OUR ANTIBODIES!” the others chanted.
“OUR BODIES!”
“OUR ANTIBODIES!”
“Ok, ok!” The double doors of Anticine Incorporated whooshed open, and Jeff hurriedly rushed into its embrace. He stopped just inside, scanning the lobby timidly. Serene, white surfaces glimmered in warm yellow light, illuminated by the panels inset into the ceiling. A few people milled about, and a dozen more sat in several rows of chairs, waiting to be called up to thereceptionist’s desk. No one acknowledged him, and yet Jeff still felt out of place.
“Hello there,” the receptionist smiled at him. “Welcome to Anticine Incorporated. I’m sorry about the people outside. That usually doesn’t happen.” She gestured for him to approach.
“Don’t be shy. Is this your first time here?”
“Uh… yeah.” Jeff mumbled as he shuffled towards her.
“My name is Sarah. How can we help you today?” She eyed the voucher in Jeff’s hand. “A voucher! Congratulations on being selected! Just hand that over, along with some ID, and I’ll take care of everything for you, OK?”
“Thanks.” He gave her the voucher and fished out his driver’s license. “Will this work?”
“Yup, that’ll do!” She typed some more, then placed a hand on his, “Don’t worry about a thing, hon. Everything will be alright.”
“Is…is it going to hurt?”
“We will need to take some blood, so unfortunately you will feel some discomfort.” Sarah patted his hand. “But no more than that! Now please go down the hall to my left, and take a seat in the waiting room, OK?”
Jeff nodded and proceeded down the hall. The voucher worked! I can’t believe this is really happening! He swallowed his excitement as he entered the waiting room at the end of the hallway. More important-looking people were sitting in comfortable leather-lined seats, waiting to be called into one of several examination rooms.
As he took his seat, he overheard a terse conversation between an impatient man and a nurse. “I have been waiting for an hour! I was told that my formulations were ready yesterday!”
The nurse smiled apologetically, “I’m sorry about the wait, sir. We performed a final quality control test and we found that the formulations weren’t fit for injection. This happens rarely, and I am sorry to have wasted your time. But at Anticine, we’d prefer not to give our clients a new allergy when we’re trying to remove one.”
The man grumbled and checked his tablet, “Let’s reschedule to next Wednesday.”
“Of course, sir.” She watched the man leave before settling her eyes on Jeff. “Mr. Williams? Jeffrey Williams?”
Jeff nodded, jumping up from his seat. The nurse beckoned him into an examination room and closed the door behind them.
“Nice to meet you, Mr. Williams. My name is Karen, and I’ll be walking you through the process today. It says here that this is your first time at Anticine Incorporated, so I need to give you the introductory spiel. Sorry if I sound like a commercial.”
She cleared her throat and went on autopilot, “Here at Anticine Incorporated, we take in patients and edit their immune system to rid their body of disease. It is a natural process, where we add or subtract antibodies from the patient’s immune system, antagonize or tolerize substances, and then let the body heal itself in whatever manner it sees fit. We pride ourselves on the high quality of our work, and on our vast capabilities to alter the immune system in a minimally-invasive way. All it takes is a couple of injections. Please call today to book an appointment.” Her eyes refocused on Jeff. “Sorry, that last part actually was from a commercial. Anyway, do you have any questions?”
“You’re… you can remove my diabetes, right?” Tension knotted inside as he waited for her answer. He felt the ghostly sting of thousands of past insulin needles poking into his gut before Karen merely smiled and nodded.
“Well, it says here: Type 1 Diabetes, auto-antibodies present.” She patted his hand, “Let’s remove those bad antibodies first, shall we?”
Jeff nodded, “So… you’re going to filter my blood?”
Karen smiled again, “No, but I will be taking a sample of your blood, and a bit of your bone marrow as well. First, we’re going to identify exactly which of your antibodies are targeting your insulin-secreting beta cells in your pancreas. Then, we’ll look at your bone marrow and find the B cells that produce those specific antibodies, and then come up with a formulation that eliminates those cells!”
“How are you going to do that?”
“We have an artificially intelligent, machine learning protocol that uses the Anticine Database of Antibody Structures to predict and solve the structure of both the bad antibody, and the membrane of the B cell that made these bad antibodies. Then, we’ll generate our own antibody that targets and destroys this bad B cell! Then no more bad antibodies!”
“What?” Jeff asked incredulously.
Karen pursed her lips in thought. “Think of it this way. There’s a sidewalk outside with still-wet concrete. If I step in it, it’ll have my shoeprint! My shoe will also get stuck in the sidewalk and ruin its aesthetics! What we’re doing is taking my shoes, looking at its size, shape, age, serial number, and purchase date. Then we’re going through the city records until they find me and get me to stop stepping in wet concrete! Does that help clear things up?”
Jeff scratched his head. “The shoe is the antibody?”
“Yes!” Karen beamed, “If you would like to get started, here are the forms that you need to sign. I’ll go prepare the necessary equipment.” A small parcel of forms suddenly appeared in his lap.
“I’ll be right back!”
She was gone in a flash, leaving Jeff staring at the packet before him. It sounded like magic to him. They were going to figure out what the troublemaker antibodies looked like, and from that, figure out which of his immune cells were making them? Then make their own antibody to remove those immune cells? He picked up a nearby pen and searched through the papers. They were definitely written in English, but most of it was unintelligible.
Jeff finally found the line that awaited his signature. I just have to sign this, and my diabetes will be gone? He thought about all those times when his insulin alarm had gone off embarrassingly in front of his boss and his coworkers. He thought about all those needles that he jabbed into his gut every time those alarms went off. The sharp pain, followed by the blood rushing to his face as he blushed with shame and humiliation. If he gave into the shame, he’d suffer the effects of unchecked diabetes: fatigue, blindness, brain swelling, coma, and worse. He thought about the insulin shot that awaited him this afternoon, and all the others that followed in the days and years
to come.
He signed the forms.
Jeff placed the packet on the bedside table, and climbed into the bed. As he waited for the nurse to return, he noticed that the TV hanging in the corner was showing a special news report. A smartly-dressed news anchor gesticulated dramatically. “We just heard the opening remarks in the lawsuit against Anticine Incorporated! Pollux Pharmaceuticals, along with several special interest groups, are alleging that Anticine Incorporated is violating laws by patenting naturally-occurring biological information and illegally profiting off of their patients’ antibodies!” The scene switched to a man dressed in a white lab coat as the news anchor continued, “I have Dr. Simmons from Anticine Incorporated here to give us the company’s perspective.”
“Thank you for having me! First, let me clear up some misinformation that Pollux Pharmaceuticals has been spreading. They’ve been losing market share since Anticine’s vaccines are so effective at stopping infectious diseases in their tracks! Anticine does this by using our neural network, along with our Antibody Structures Database, to quickly produce antibodies using vaccines, and produce vaccines from antibodies. Although this database is built from patient information, we use this information to generate new antibodies, and never just mass-produce someone’s antibodies. It is no different from genetically engineering a new plant using DNA information from other organisms.”
“And what about the epidemic occurring in southern Europe? Many special interest groups have alleged that the rise of enhanced HIV is directly caused by Anticine’s manipulations with the human immune system!”
Dr. Simmons adjusted his glasses, “I would hold off judgement until more data has come in. We have always used the immunological defenses of other organisms in medicine. But the penicillium mould still exists in the world, even though penicillin-resistant bacteria has made its immunological defenses obsolete. We don’t have any conclusive data that our ability to edit our own immunity will make the entire human immune system obsolete.”
The news anchor continued, “There has even been criticism about Anticine’s Voucher Program, in which anyone can purchase a voucher to be redeemed for free immunotherapy treatments. The purchaser could choose to give the voucher to someone they know, or allow Anticine to choose an applicant. There have been reports of patients refusing chemotherapy and gambling on the chance of receiving a voucher in the mail!”
“That is certainly unfortunate, but no one can deny the fact that thousands of people have already been cured of their chronic conditions and diseases through the voucher program. These people would otherwise have been unable to afford such personalized therapies.” Dr. Simmons straightened his lab coat. “They were healed by the compassion of human beings who are in a position to help their fellow man. I think this altruism is a wonderful thing, and something that shouldn’t be disparaged.”
That’s why I’m here. Jeff thought about the cardboard coupon that had appeared in the mail yesterday. There had been a small message on it from the donor.
Whoever you are, I hope this voucher eases your burdens and brings you relief.
Joshua Edwards
He had no idea who Joshua Edwards is, and would probably never get to thank him.
The door swung open and Karen swept back into the room, holding a tray filled with tubes, containers, and a few needles. “I’m back!” She announced brightly. “Have you signed the forms?”
“Yes.” Jeff nodded. He winced at the sight of the needles. His long history of insulin jabs had not dulled his wariness towards sharp metal objects.
Karen flipped through the authorization packet, “Everything looks in order. Are you ready to begin? I’ve got local anesthetics to help dull the needle pokes a touch.”
Jeff gritted his teeth. Another couple of needles, and then no more! That, and the diabetes is a pain as well. He flashed a nervous smile. “I’m ready. Please remove my diabetes.”
As Karen extracted what Anticine Incorporated needed, Jeff’s thoughts retreated inwards. Mom will be so happy when I tell her about this. Dave and rest of the crew won’t believe I got an Anticine Voucher in the mail. Hopefully the receptionist gives it back when I leave. Gotta show boss why I gave such short notice about taking the day off. I think he’ll understand.
Karen paused, “Everything ok there?”
“Just thinking about how lucky I am.” Jeff replied quietly, wincing as a needle entered his arm, “I… never would have been able to afford this treatment.”
She smiled, “Well, I’m glad you are here and getting treated. It makes me feel like I’m making a difference when I’m removing diabetes from someone in need, rather than a pollen allergy from another rich bigwig. Anyways, I’m all done here.”
“Already? I didn’t even feel anything.” He checked her tray, and sure enough, the tubes were filled with his blood and some other liquids.
“Well, you’re not cured yet, if that’s what you mean. Make an appointment in 2 weeks, and then we’ll be able to remove your pesky auto-antibodies then.” Karen opened the door and waved Jeff through, “Oh, and one last thing I forgot to mention.”
Another packet materialized in Karen’s hands, “Anticine’s ability to edit immune systems relies on its antibody database, and one of the ways that we build this database is by identifying and adding our patients’ antibody profiles. With more antibodies identified, our machine learning software can generate accurate structure solutions, faster.” She fluffed the packet in her hands.
“Anticine’s ability to quickly synthesize vaccines for infectious diseases also relies on this database. There are 8 billion people on this planet, and everyone’s been exposed to different pathogens and unknowingly fought them off. There are many hidden immunities in all of our bodies, just waiting to be discovered. We can take your antibodies, figure out their structures and generate vaccines that would be useful in other parts of the world.”
She looked into his eyes hopefully. “But we don’t do this without the patient’s express consent. So, Mr. Williams, will you let us add your antibody profile into our database, and help us cure other people like you, in the future?”
The TV program flashed into his mind, along with images of the protesters outside. They were so angry about a corporation profiting off the antibody information from regular people like him.
But Anticine Incorporated wasn’t just saving lives, it was also improving the quality of those lives by removing chronic, debilitating diseases. Jeff doubted that he could ever make enough money to buy a voucher for anyone, and if there was even a chance that his antibody profile could give someone else the feeling of freedom that he felt now, there was no other answer to Karen’s question.
“Yes. Add me to the database.”

THE BODY

by Courtney Hilden

Sometimes it becomes clear when a kin group is hoarding too much and has taken away from the larger community. When that community decides to take action, my team and I get called in.
The job, usually: go into the residence that the kin group has already been evacuated out of, go through the residence’s things, catalog them, allow the Council, separate from the community, to make a decision about the belongings, and then package them as the community sees fit.
But there was this time I was called out to Swan’s Way, located in the Aldebaran system, for a job, and although it looked like a standard job on the outset, it turned out not to be.
Swan’s Way used to be an oasis, but after some poor management decisions four hundred years ago, it’s a dry, though not humid, desert. There’s not much there anymore, just farmers maintaining and harvesting energy from the solar panels. Everyone jokes that Swan’s Way has more panels than people, and that’s always been my experience too. The family we were investigating had been convicted of excess, and so that means they’d probably have quite a few things that needed cataloging and moving.
And it was, as expected, a fairly nice house. It had tan walls and dark wood furniture. There were tall ceilings and large windows.
I was actually in the other room when Canis found it, sweeping out glass that had been shattered on the floor.
“Mirfak, come in here. You’re going to want to see this,” Canis said. I had heard that a thousand times before, so I didn’t hurry. I figured it was going to be some ridiculous art that indicated just how guilty this family was of excess.
Instead, it was a person. Or it looked like a person, at least in the shadow. I came closer. It wasn’t quite a person. Sure, they were the typical morning gray color, with a normal set of breathing and eating holes on their torso, but the head was unmistakably not a real head, but a mechanical one. It was crude, with a corner smashed in.
It smelled terrible. Its breathing holes were crusted over and its food hole had a great smear of orange over it.
Eyes had been drawn on its mechanical head, but they obviously had no function other than to make the creature less horrifying.
I suspect Canis knew what I was thinking. “The eyes don’t really fulfill their function, do they?”

I brought the body back to the Procyon system, where we happen to have a headquarters. It’s a warehouse essentially, since sometimes we have to spread people’s possessions out on the floor, sometimes we have to photograph them. Sometimes we put them in storage, but the central room is mostly bare unless we are working a case. Regardless of our active case status, there’s always a few desks we move around the room as needed, with some computers set up to handle any tech we get, and our work tablets, which we use for correspondence and creating lists. I called in Crieff, an old friend of mine who has done some healing work. I watched him as he
silently did a check on the body’s outside.
“Someone is very clever,” Crieff said. “This body is indeed someone’s real body, or it was, once. Can’t be sure.”
“Who’s?”
He shook his head. “I don’t know. This body was never marked like we do with all babies.”
“How did they create this?”
“The mind is the seat of consciousness, personality, self, identity. But the body can go on without the mind, if fed.” He turned to Canis. “It has been starving well before you found it. Please go find it some food.” Canis happily left the room, her eyes staying on the body the entire time.
“Considering this family was convicted of excess, I am assuming this was a servant,” I said. “Who would allow their body to be removed from their mind?”
“I don’t believe it was voluntary. Did you carry it here?” he asked.
“Yes.”
“You could have given it directions and it would have walked here on its own.”

I was hoping Crieff would have some thoughts on the body’s identity, some trick of getting it to talk, because it didn’t have the kind of mouth with vocal cords attached, but it didn’t initially, so I had to ask to see the file on the kin group, something I have never, in all my long years of cleaning, have ever asked to see.
I looked through the Enright kin’s paperwork, and it was clear how they had been convicted, just looking at the discrepancies in their financial filings. But at the back of the file was a set of pictures, and my stomach dropped when I saw them. All of them had the same morning gray skin.
Canis looked over my shoulder. “So they hadn’t kidnapped anyone?”
“Almost certainly not. There is no need to inquire to surrounding communities if someone had gone missing. No one was missing this person.”
“But there’s no one in these pictures with that exact pattern of breathing and eating holes.”
“I think they were wise enough not to let the servant take pictures.”
“Or the servant was taking the picture.”

Council was not amused. “Are you telling us that the kin in question had killed someone via decapitation, then stuck a mechanical head on it?” one of them asked me.
     I had tinkered with it in the days in between, trying to be gentle. “Possibly,” I said. I removed the front metal plate on the head. There were a mess of wires inside, and a motherboard. “I think it was a servant. It’s programmed to do certain things in a pattern over time. It is programmed to cook five times a day, clean once a week, and otherwise lay in a certain position in the room it was found in. But someone tried to reprogram it recently, the last time it was accessed, and it was a bad job, because I don’t think it could move after that.”
One of the other councilors raised her eyebrow. “A certain position?”
“I think it was possibly being used for breeding, or at least was intended that way. I cannot be certain it was actually used like that before your good council had the kin evacuated.”
“What do we do with it now?”
“I was of the mind that we should have the mechanical head removed, then leave it to die naturally of starvation. Then I thought perhaps a bayonet would be kinder, quicker. But I am increasingly of the mind that we should have it programmed for optimal self regard, then allow it to live the last of its days here.”
“There’s been debate about optimal self regard,” the first councilor commented.
“Nothing rivaling the self regard of the kin group from which is originated from,” I said.

The Council took time with their decision, and in the meanwhile, I found it unnerving. Canis wiped the software, at the behest of the Council, which at decided that was the bare minimum that should be done. After that, we had left it in the office, sitting in a chair in the corner under the control panel, and Canis and I worked as normally for the rest of the day. The rest of the Enright things had to be organized. We got some of it done, but there were still piles of clothes, a few electric tablets, furniture of various sizes, an extravagant collection of artwork, including one I quite liked of a crane, and an old school 3D printer.
After Canis went home, I cleaned up. I went to turn off the lights at the control panel, and there the servant was, staring back at me. There was something not right about this, but I couldn’t quite figure out what.

     When we came back the next day, both of us stopped when we saw everything. All the clothes was folded, and in piles. The electric tablets, which had collected dust, had been cleaned. I picked up one of them, plugged it into our computer. “It’s been wiped clean. Did you get to that yesterday?”
Canis looked back over at me. “You didn’t do it after I left?”
There was a clanging sound, and we both jumped. We turned to see the servant, also clearly having just jumped itself.
     “But the programming was wiped clean,” I said, feeling deeply stupid. I turned to Canis. “Didn’t you…?”
     “I did.”
It titled its neck at us, with those eyes that never changed. It slowly raised its hands.
“It’s okay, it’s okay, everything’s fine,” I said, raising my hands too. Canis followed suit.
“Can you—” then I realized how stupid my question was. There was no way to answer. “Give it one of our tablets and a stylus,” I said to Canis.
     It slowly reached down to the table and picked up a stylus, keeping its other hand up.
“Well, that answers one question,” Canis said.
It wrote, though its hand shook. It held the tablet up. It read I am sorry for scaring you .

Crieff came out again. We left him in the office, alone with the servant, while we waited outside, sitting on the bench next to the front door. It was a nice enough day, but I think both our minds were elsewhere. When he came out the door, we both stood quickly.
“It’s fine,” he said. “It can hear you.”
“But how is it moving?” I asked.
“The stomach has a bundle of nerves, a secondary brain. When the body lost its first mind, it was able to move functioning to its secondary brain. Probably would have never happened if they hadn’t sustained the body in other ways.”
“But then why use the fake head and the programming?” Canis asked.
“I think the programming was to suppress the secondary brain making its own choices.”

The Council didn’t respond immediately when we sent a message about this development.
“The Council might take awhile,” I said to Canis as we worked at our desks. “Without a primary brain, I’m not sure if it even be a self, since the seat of itself is gone.”
“It’ll never have its identity again, whatever it was in its real, first life.”
“Perhaps that’s for the best.” We both looked over at it. It was sitting in a chair. It did the head tilt again. It slowly raised its arms again and took the stylus next to it. Canis handed it a tablet.
We watched it jerkily write again. No life .
“Do you mean—” Canis stopped herself.
It began to write as quickly as possible. It had to stop, slowly clean whatever it initially wrote, and try again. Enright ?
Canis and I exchanged another look. Thank God it couldn’t see.
“You kin,” I said. “Have refused to communicate with us. Possibly for legal reasons.”
It straightened suddenly.
“Your kin were convicted of excess,” Canis said. “What do you—?”
“It began to furiously write something. It held it up. Neither of us could read it. “I’m sorry,” Canis said. “What are you trying to say?”
Another attempt, with shaking hands. Auteuil Illiers .
I usually never use my work tablet for something like this, but I searched that name in the database. Canis also busied herself with her tablet.
The Auteuil clan had lived in Swan’s Way. I opened one of the files in the database and saw an old murder investigation from years ago. It had been a small group, but they had all died.
“I’m sorry,” I said. Before I could say any more, Canis turned her tablet to me. It was a picture of the Auteuil clan. In the background, there was an old 3D printer and a set of extravagant paintings.
I flipped through the murder file. I stopped at an image of Illiers. He was a painter. He was midway through a crane’s wing. I turned to the painting, propped up against the opposite wall. I turned my tablet around so Canis could see it.
I took a deep breath. “Our records indicate that Auteuil Illiers died four years ago.”
Its shoulders slumped. It stopped moving long enough that I thought perhaps it had turned off or had a circuit overload and couldn’t anymore. And then it curled up into a ball, still sitting in its chair, hugging itself.

KEEPING HOPE ALIVE

by Divya Raman

If it were not for hopes, the heart would break. I trace the cursive letters of these words embroidered on the edge of the blanket draped over my arm. I remember hearing those words for as long as I have lived. For the first time, as my great grandmother whispered it to my mother when I was born and they discovered I had a heart defect; from my mother, each time I came out of a surgery that tried to fix my failing heart; and I heard it like a refrain in my mind as I saw the grim faces of my doctors as they studied the heart of my unborn daughter on their screens.
My great grandmother lost her daughter in 1949, after a traumatic birth at home. She never knew what ailed her baby; all that she knew was that less than a day in this world, the little girl she had wanted all her life turned blue and stopped breathing. She had all her other children in the hospital after that, surrounding herself with doctors and nurses who she revered as if they were messengers from God. But she never got over the loss of her baby girl; never forgave herself for not having noticed her baby’s color or breath. For every child born into our family after that, she made it a point to be there, keeping a keen eye on the newborns through their first weeks. It was she who noticed when I started to pale a few hours after I was born; it was she who rushed out and called the staff in a firm tone; it was she who watched the screens and asked the doctors questions my mother was too overwhelmed to think of; it was she who had this blanket made for me when I was just a few months old. I wish she was here now, telling me to keep my hope alive.
I was born with a hypoplastic heart. When I was little I used to call it a plastic heart , wondering if my Princess Barbie had one of those inside her plastic chest. Later a doctor told me that left side of my heart was not as big as it should be, so the right side of my heart was trying to do more, and was getting tired. It would take a series of three surgeries within my first five years to help my heart get better. My first surgery was when I was a week old, and it was intended to get me through to 6 months. At 6 months, I had another surgery to reduce the load on the right side of my heart. I once saw of picture of me taken on my first birthday and I looked small and blue;
there were tubes connected to me. You wouldn’t have known I was a year old if it wasn’t for a large balloon tied to my crib. I had my third surgery when I was 3 years old. It was the last of the series, and the doctors knew that my only option after that was a heart transplant.
I had a quiet childhood; I was on medications and a feeding tube and my parents didn’t take me out very much for fear that I would fall sick. They finally enrolled me in school, but I barely made it through a month of Kindergarten before my heart started failing again. I was put on a heart transplant list and taken out of school. My mother and I would spend the days under the tent canopy on my bed, snuggled in blankets reading from a pile of books. Sometimes she would fall asleep and I would quietly take her phone and play a game. I remember the day I pressed something and opened an article about transplants. I couldn’t read all the words, but one line
was written in big text and I sounded my way through it: “58 children died while waiting for a new heart”. My heart sank, and I turned off the phone quickly, worried that my mother would see what I was looking at.
My mother got a call about a heart for me just before my seventh birthday. Within hours we were on our way to the hospital, ready for a surgery that was going to happen at midnight. My doctor came in and spoke to my mom. He then turned to me and told me that I would fall asleep and when I woke up there would be another heart in me, and I would start to feel better.
“Where did you get the heart from?” I asked.
The doctor paused and looked at my mother. Slowly he said, “Your new heart used to belong to a little boy who died yesterday because he was in an accident.”
All I could think about was that for me to live, a little boy had to die. I nodded slowly. “Tell his mom I’ll keep his heart safe forever.” And I have done exactly that for over 20 years now.
When I was in high school, I learned that my heart condition was genetic; that my great grandmother’s daughter likely died undiagnosed from the same congenital heart defect I had. The geneticist suggested that there was a chance that if I had children, I would pass along this trait, resulting in my child having the same congenital heart defect. Even with this knowledge, I knew I wanted to have children of my own. Armed with hope and science, I conceived my first child and opted for all the extra scans to monitor her growth. At 20 weeks, they started to see some abnormalities in my daughter’s heart and found the same genetic trait in her as I had. I
knew that we were about to embark on another long journey, and I was determined to do all that I could to make it a little easier for my little girl.
I found a famous surgeon at a heart center on the other side of the country and asked her for all my options. As she started naming series of surgeries and transplant options, I stopped her. “Tell me the about something that didn’t exist 30 years ago”, I said. Little did I know that what she would tell me next would completely change my daughter’s life.
She described a new artificial heart that was still in clinical studies; it was made from a bioabsorbable material that would let my daughter’s cells grow onto the surface, making it her cells and her tissue over time. They would be able to make one that was the right fit for her little body when she was born, and over time it would grow with her, minimizing the need for multiple surgeries over her first few years. It had a small electrical component that would make it beat to circulate blood, and a battery that we could charge wirelessly. “That’s it!” I said, “That sounds perfect.” I was elated; my daughter’s life would be different. She wouldn’t spend her first few years with tubes and surgeries; she wouldn’t look blue on her first birthday; she would go to school; no other child would need to die to allow her to live.
The surgeon continued, “The lab results show that your daughter has the same genetic disorder that you and your great grandmother carried. We can also start some gene therapy in utero that will change the mutation as she is developing. She will need to continue to have a few treatments after she is born, but the research shows that gene therapy can be very effective if we start it earlier in gestation. You will need to plan to come in for those appointments and we’ll also need to get you in the center for some imaging over the remainder of your pregnancy.”
I was surprised. “Gene therapy before she’s born? Is that safe? And why do I need imaging?”
The surgeon nodded. “Gene therapy is safe to deliver through the amniotic fluid. We’ll monitor how effective it is once she is born, but we’ve had a few cases where the child needed very few additional treatments because we started so early in the pregnancy. The imaging is to allow us to prepare your daughter’s implant before she is born. Our scanners are strong enough to safely see all of your little girl’s heart and vessels as they develop. We’ll start to take some pictures so we know exactly what shape and size her new heart needs to be, and we can have it ready for her once she is born.” She paused and looked me in the eyes. “We don’t know how stable her heart will be when she is full-term; we need to be ready to act at any time. We will monitor you closely for your final weeks. If everything looks normal, you can have a regular delivery and spend a few hours with your daughter before we start the surgery. However, if there is any sign of distress, I recommend that we complete an emergency C-section and get your daughter into surgery immediately.”
I gripped the side of the chair I was sitting on. “Will she be okay to have the surgery so soon after she’s born?”
The surgeon didn’t waver. “It is a complicated surgery, and as with a transplant, there are a lot of factors to do with the body starting to properly absorb the material. All the data on this product has been in adults, so your child will be the first to experience this procedure. The results for adults look very promising, and I believe it will be equally beneficial for a child. But there is always a risk. We will monitor your daughter closely after surgery, and will need to keep
everything in check for the first year or so.”
For a moment, a dark cloud of doubt blinded me. Was gene therapy the right thing to do?
Changing my daughter’s genes before she was born sounded like playing God. Would changing her genes change the fact that she was my daughter; my flesh and blood? Would I be cutting off her ties back to my great grandmother? Was it worth it to give up a piece of family heritage to know that she could have a family and never worry about this for her child?
Was subjecting my daughter to a new heart implant the right thing to do? Should I instead let my child go through the same experience I had, and feel safer in knowing that it may extend the time I have with her? Should I hope for the untimely death of some other child in order to gain a transplant heart and life for my own? If I went into an emergency C-section and then lost my child to surgery, would all of this have been for aught? Would my heart ever mend from that sorrow? If all I got was a few hours with my little baby, would that be enough time to make memories to last me the rest of my lifetime? I felt as if I was drowning, but then heard my great
grandmother’s voice: If it were not for hopes… I took a deep breath and faced the surgeon head on. “I understand; we’re going to fight for this. I’m ready to show my daughter how.”
My daughter, Zita, my little hope, was born in an emergency C-section and then whisked away to the OR where she received her new artificial heart, which had been waiting for her, ready to become part of her and to give her a new life. I finally got to hold her 2 days after she was born, but it was worth the wait. I traced her chest incision and hoped that it would be the only scar she would bear in her life. I marveled in her pink coloring and could not stop the tears of joy as she
held onto my finger for the first time. We have been back to the hospital many times over her first year, taking all the extra precautions to make sure that her body is absorbing the tissue and that her heart is working as it should. She has also completed two additional gene therapy treatments to remove the mutation that my great grandmother passed down.
As I wait in the lounge for the nurse to bring her back from her final set of scans, I know that I will miss the safety of this building; it’s a place where I lived my scariest nightmare, but also realized my biggest dream. I see the cardiologist walking towards me and I stand, immediately worried.
He smiles and gestures for me to sit. “Things are looking good with Zita. You can take her home, and we can start to see her every 6 months, unless you need to bring her in sooner.”
I swallow, not knowing how to put my biggest fear into words. “How will I know if something is wrong?” I ask.
The cardiologist nods and pulls out a phone. “Just call me; I can see all of the information from her heart here.” He opens a screen that has Zita’s name at the top. I watch the dancing waves showing the beating of my daughter’s heart. I finally smile and realize that I can feel safe even outside these walls.
I know hope is only one part of our story. Science and the human drive to forge new paths are the bigger parts. Hope kept my mother’s heart from breaking, and now it will keep mine intact. Science kept me alive, and it has now given my daughter a whole new chance at living.

Thanks to everyone and we’re already looking forward to hosting next year’s Medgadget Sci-Fi Writing Contest!

[email protected] picks 32 for digital health cohort

Boston skyline across the Harborwalk

Building around the strong reaction to its inaugural digital health cohort this season, [email protected] expanded on the party’s theme of champions for example hospitals, insurance, technology and pharma companies picking the startups they would like to use. The 2018 cohort will pair two champions with each one of the 32 startups selected for that six-month program.

The Heart Beat program is tailored for later stage firms that will be ready to scale, have elevated a maximum of $5 million, and generate under $5 million in revenue. The aim of this program would be to connect selected startups with proper relationships, sources, mentoring, and community access required to create an effect in digital health. Like an increasing number of accelerator programs, [email protected] takes no equity in the companies.

Even though it would appear such as the priorities of say, a pharma company along with a hospital would differ, Nick Dougherty, the program director for PULSE, stated in a phone interview the champions did a great job to find partners with shared goals.

Although Boston Children’s and Cerner were the only real partners he known as out by name, other types of partners using a startup incorporated a pharma company along with a provider, along with a payer having a provider.

“What you receive is really a clinically valuable technology that can also be highly implementable,” Dougherty stated.

He noted that certain partnership he was particularly happy with could be that the Massachusetts Executive Office of Elder Matters works using the state’s eHealth Initiative, which oversees digital health initiative. Another was AARP and Campbell’s Soup.

There’s been lots of curiosity about developing technology to aid the power for seniors to reside individually for extended from getting a means to see relatives caregivers to remotely monitor them, medication adherence and nerve assessments to recognize cognitive function changes earlier.

The incoming class has more geographic diversity — only 15 startups participating come from Massachusetts in contrast to 21 this past year.  Listed here are the people from the cohort

Astarte Medical Partners, that was a finalist within the Impact Pediatric Health competition at SXSW this season, created a clinical decision support tool for Neonatal care physicians. The merchandise gives an introduction to clinical data instantly to evaluate the condition of the preterm infant’s gut health. The organization relies in Yardley, Pennsylvania.

Epharmix in St. Louis created a platform that mixes triage with patient outreach to follow along with-up through automated telephone calls and emails using the sickest 20 % from the patient population through disease-specific interventions. The organization has gotten investment from Health X Ventures and cofounder and Chief Financial/Operations officer JoeMcDonald highlighted the difficulties of applying population health technology in an article for that MedCitizen portion of MedCity News this past year.

Epion Health in Nj continues to be in this area for some time,  The practice management support business targets increasing the check-in process for doctor’s offices. Its tablet interface helps practices get patients’ health background, medication information. It may also help practices with collections by getting patients review their insurance plan, co-pay and outstanding balance information. Relevant data joined by patients could be integrated having a patient’s electronic health record.

Take a look at all of those other cohort people below:

aam
Massachusetts

Aluna
California

BOLD Medical Partners
Illinois

Day Zero Diagnostics
Massachusetts

DeepHealth
Massachusetts

DocFlight
New You are able to

DynamiCare Health
Massachusetts

Edification Project
Massachusetts

Epidemic Solutions
Massachusetts

Fitly
Pennsylvania

Folia Health, Corporation.
Massachusetts

Healthimation
Massachusetts

HealthRhythms
New You are able to

InsightRX
California

Leuko
Massachusetts

macro-eyes
Washington

Medumo
Massachusetts

Moving Analytics
California

Multisensor Diagnostics
Maryland

Nutrimedy.
Massachusetts

Orbita
Massachusetts

OZONE.ai
New You are able to

Pillo Health
Massachusetts

SafeInHome
California

TailoredCare
Wisconsin

TelaDietitian
New You are able to

ThinkGenetic
Massachusetts

TORq Interface
Massachusetts

Unima
Mexico

Photo: DenisTangney Junior, Getty Images 

MedCity ENGAGE, October 23-24 in North Park, concentrates on the most recent strategies and innovations to boost patient engagement, care delivery and company wellness. Use code MCNTAG in order to save $50.

Koch Disruptive Technologies to guide $150m investment of INSIGHTEC

Printed 15 December 2017

Koch Disruptive Technologies, a subsidiary of Koch Industries, may be the lead investor inside a $150 million Series E funding round for INSIGHTEC, an industrial-stage medical device company revolutionizing surgery with MRI-led focused ultrasound.

An investment, announced Thursday, allows the organization to help commercialize its approved indications, in addition to continue research in areas for example Parkinson’s disease, Alzheimer’s and brain tumors, while using company’s breakthrough technology to provide treatment inside a non-invasive way.

 It can also be the very first investment for Koch Disruptive Technologies because the business group, brought by KDT President Chase Koch, commenced operations in November.

“This investment aligns well using the founding concepts of both Koch Disruptive Technologies and Koch Industries,” stated Koch. “Having a history of driving innovation and improving patient outcomes, INSIGHTEC has itself invested and expanded its abilities to succeed surgical medicine to enhance the and excellence of existence of countless patients.”

“Hospitals all over the world are more and more going after incisionless treatments for his or her patients using our focused ultrasound therapy,” stated Maurice R. Ferré, MD, INSIGHTEC’s Chief executive officer and Chairman from the Board, that has brought multiple transformative medical technology companies throughout his career. “This investment round elevates INSIGHTEC right into a new proper position inside the healthcare industry.”

INSIGHTEC’s Exablate Neuro may be the first focused ultrasound device authorized by the Food and drug administration to deal with essential tremor which has not taken care of immediately medication and lately received the very best Medical Technology award by Prix Galien.

The organization surpassed the fir,000th patient milestone captured, essential tremor people are routinely receiving treatment with focused ultrasound at 40 medical facilities all over the world.

Using more than 20,000 procedures for a variety of clinical applications already performed using its technology, this investment allows INSIGHTEC they are driving further purposes of MR-led ultrasound to deal with Parkinson’s disease, cancer of the prostate, liver cancer and pancreatic cancer. Clinical research using the company’s technologies have already effectively disrupted the bloodstream-brain barrier, which holds the opportunity of targeted drug delivery to deal with Alzheimer’s and brain tumors.

“Transformative ideas know no borders and may originate from anybody, anywhere,” stated Steve Feilmeier, Executive President and CFO, Koch Industries, Corporation. “We’re well-positioned to harness these breakthroughs happening around the world and also to also support generation x of promising entrepreneurs.”

Jefferies LLC, the worldwide investment banking firm, advised INSIGHTEC for that investment round. Existing investors in INSIGHTEC include Elbit Imaging, You are able to Capital, Focus Holdings, GE Healthcare, GEOC, and Meditech Advisors. INSIGHTEC is headquartered in Haifa, Israel, and Miami, with offices in Dallas, Tokyo, japan and Shanghai.

Source: Company Pr Release

Magnetically Led Bacteria Move With confidence Within Strong Currents, May Soon Deliver Drugs Inside Body


Researchers at Queen’s College in Canada have were able to get a special kind of bacteria to go swimming against a powerful current, opening the potential of while using microorganisms as drug delivery vehicles. They is using magnetotactic bacteria which have magnetic crystals within them not to mention orient themselves using the Earth’s magnetic field. By establishing the exterior magnetic field, they could coax the bacteria to maneuver in foreseeable ways and directions.

Typically, magnetotactic bacteria are uncovered towards the Earth’s magnetic field and natural currents inside the physiques water they inhabit. The Queen’s College team uncovered the bacteria to stronger magnetic fields and more powerful currents to find out if they’d manage swimming correctly under drastically different conditions.

Within their experiments, they observed the bacteria swimming across rapidly moving currents, even if your magnet was gone to live in be oriented verticle with respect towards the liquid’s flow, a rather abnormal occurrence.

Getting proven the magnetotactic bacteria can travel through difficult environments much like individuals based in the body, they now intend on focusing on attaching different drug compounds towards the bacteria. If everything goes as wished, we might soon visit a new treatment model by which countless drug-laden bacteria are injected adopted through the patient standing in the magnetic atmosphere that suggests the bacteria where you can flow toward a preferred target.

Study in journal Small: Magnetotaxis Enables Magnetotactic Bacteria to Navigate in Flow…

Via: Queen’s University…

Editors

At Medgadget, we set of the most recent medical technology news, interview leaders within the field, and file dispatches from medical occasions from around the globe.

FlexScanMD and drchrono get together to assist medical practices track inventory

Earth planet with global routes and light dots representing global connection and communication.

Within the healthcare world, monitoring product inventory is vital. But oftentimes, problems arise because of an organization’s disparate systems. Whenever a practice’s systems aren’t linked, staff people may finish up putting things off and entering duplicate data.

A brand new partnership between Electronic health record vendor drchrono and FlexScanMD, a listing keeper company, aims to alter that.

With the collaboration, FlexScanMD has integrated with drchrono’s EHR system and exercise management platform. Therefore, all updates can have in both FlexScanMD and drchrono. Jetski from users from getting to by hand copy information and make sure the information in various systems.

“This partnership can create a seamless and unified workflow that can help make practices more lucrative and thru error reduction, improve patient outcomes,” Aaron Gerber, FlexScanMD’s director of economic development, noted inside a news release.

FlexScanMD’s cloud-based platform has a number of unique components. For instance, certain medical practices may use the tool to trace profits, commissions and purchasers around the products they offer.

As drchrono cofounder and COO Daniel Kivatinos stated inside a statement:

The need to precisely track inventory keeps growing and it is answer to improving efficiency among medical practices nationwide. FlexScanMD is really a effective tool with an array of features that will medical staff to achieve this. This latest integration makes drchrono’s platform a much more versatile and powerful system.

Additionally for this deal, drchrono continues to be busy in 2017.

In Feb, it inked an offer with Physitrack, a telehealth company that supports remote physical rehabilitation monitoring and patient engagement. Physitrack Chief executive officer Henrik Molin stated Apple’s Mobility Partner Program performed a vital role in getting the 2 organizations together.

In April, the Sunnyvale, California-based startup unveiled a $12 million Series A funding round brought by Runa Capital. FundersClub, Maxfield Capital and Quicken Chief executive officer Eric Dunn also participated.

Photo: Filograph, Getty Images

Risk-based IVD rules: Exactly what do they mean for that global IVD industry?

In 2013, Food and drug administration Commissioner Margaret Hamburg announced the agency was searching to determine a danger-based framework for controlling lab-developed tests (LDTs) and released a draft guidance document towards the public in October 2014. This trigger a deluge of reviews, petitions, and debate inside the LDT community, labs, and beyond concerning the legality from the suggested regulation and broader questions regarding how in vitro diagnostics (IVDs) are controlled within the U.S. and abroad.  

Yet 2 yrs later, the Food and drug administration required one step away from going after the danger-based regulatory framework, indicating the company wouldn’t aim to finalize the draft guidance document. Even though many in the market recognized this decision, the Food and drug administration has clearly not abandoned the problem entirely. Only a couple of several weeks next announcement, the agency printed attorney at law paper around the subject which highlighted the possible lack of uniformity between LDTs and IVDs, noting presently not every assays are exposed towards the same premarket oversight. Furthermore, the paper describes a possible regulatory framework that’s jointly administered through the Food and drug administration and also the Centers for Medicare and State medicaid programs Services (CMS), which oversees the Clinical Laboratory Improvement Amendments (CLIA) Program.

Even though the plan outlined within the discussion paper isn’t enforceable, the danger-based framework remains. Existing LDTs available on the market could be “grandfathered” in, subject simply to serious adverse event and malfunction reporting. New LDTs would consume a similar premarket review as IVDs with similar intended use. In a nutshell, despite suppressing on finalizing LDT rules, the company (together with CMS) seems to become holding fast towards the risk-based framework, a minimum of for many devices. The lately-released final guidance of Software like a Medical Device (SaMD) is a example that could impact some IVD/LDT developers, which classifies SaMD by harshness of the clinical condition and it is intended medical purpose.

Advertisement

While a danger-based framework for LDTs is novel, Food and drug administration has utilized this type of system for IVDs for a long time. Class I IVDs are individuals which don’t support or sustain human existence and also have a effective and safe profile. Class I IVDs are usually exempt from 510(k) clearance premarket review. Class II IVDs are individuals having a greater degree of risk which require special controls and many undergo 510(k) clearance premarket review. IVDs transporting the greatest degree of risk, for example individuals that support or sustain existence or have a superior chance of injuries, require premarket approval and therefore are susceptible to general, special, and ad-hoc controls as necessary.

Other nations similarly have accepted risk-based regulatory frameworks for IVDs. The Ecu Union’s (EU) IVD Directive on In Vitro Diagnostic Medical Devices 98/79/EC continues to be replaced in May 2017 through the In Vitro Diagnostic Device Regulation (EU) 2017/746. This latest regulation takes into account patient impact and classifies devices utilizing a four-tiered, risk-based system that will need roughly 80 % of IVDs undergo a conformity assessment with a Notified Body. Class A devices represent individuals using the least risk, whereas Class D is restricted to individuals using the greatest risk. This can be a substantial departure in the IVD Directive, to which most IVDs were self-declared. Particularly, safety and gratifaction data from high-risk class C and D devices should be made openly available.

Other countries have the identical risk-based system in position for IVDs. In Japan, China, and a few Central and South American countries, IVDs are sorted by risk, with Class III representing individuals devices using the greatest risk, for example dna testing, allergen testing, and bloodstream and tissue typing, while Class I represents individuals with little risk to patients. Specific country needs exist that could require additional amounts of scrutiny for many devices or different way of regulatory management. For instance, the regulatory management for IVDs in China further depends upon the foundation from the device: imported products are controlled with the central China Fda (CFDA) no matter class, while domestic devices (Chinese) are managed according to their class, with simply high-risk Class III devices controlled in the central CFDA and sophistication I and sophistication II devices managed in the local or regional offices.

As the U.S. IVD marketplace is substantial, global financial markets are expanding. IVD manufacturers searching to go in foreign markets have to consider their market planning strategy carefully to take into account evolving regulatory needs and really should use regulatory experts in individuals countries to make sure their system is in compliance. Correct classification of the system is essential.

IVDs, particularly LDTs, created for precision medicine might be among individuals impacted probably the most by risk-based frameworks, both overseas as well as in the U.S., because of their intended use and frequently, their greatest-risk status. Regardless of the FDA’s current reticence to impose risk-based classification needs on LTDs, doing this will bring the U.S. into line along with other countries’ systems for IVDs. Additionally, it may more precisely reflect the danger of the unit for patients, and assure patients and healthcare suppliers that the merchandise has gone through sufficient review just before reaching the marketplace.

Photo: Pixtum, Getty Images

Harry Glorikian
Harry Glorikian

Harry Glorikian is definitely an influential global business expert using more than 30 years of expertise building effective ventures in The United States, Europe, Asia and all of those other world. Harry established fact for achievements in existence sciences, healthcare, diagnostics, healthcare IT and also the convergence of those areas. He’s a searched for-after speaker, frequently quoted in media, and frequently requested to evaluate, influence, and participate innovative concepts and trends.

He’s presently an over-all Partner at New Ventures Funds (NV). Before joining NV Funds, he offered being an Entrepreneur In Residence to GE Ventures – Start Up Business Creation Group. He presently serves around the board of GeneNews Limited. Also, he serves around the advisory board of Evidation Health (an electronic health startup launched with support from GE Ventures), and many others. He is another co-founder as well as an advisory board person in DrawBridge Health (an innovative diagnostics startup launched with support from GE Ventures).

Harry holds an Master of business administration from Boston College along with a bachelor’s degree from Bay Area Condition College. Harry has addressed the NIH, Molecular Medicine Tri-Conference, World Theranostics Congress along with other audiences, worldwide. He’s authored numerous articles, made an appearance on CBS Evening News and been quoted regularly by Dow jones Johnson, The Boston Globe, La Occasions, London Independent, Medical Device Daily, Science Magazine, Genetic Engineering News and many more.

More posts by Author

PQ Bypass receives IDE approval to initiate study of technique of patients with peripheral artery disease

Printed 14 December 2017

PQ Bypass has gotten conditional approval of their investigational device exemption (IDE) in the US Fda (Food and drug administration) to initiate the pivotal DETOUR II medical trial.

Because the first-ever pivotal trial for percutaneous femoropopliteal bypass, DETOUR II will assess the safety and effectiveness from the DETOUR System in as much as 292 patients with lower limb ischemia because of lengthy blockages (>15 cm) within the superficial femoral artery (SFA) brought on by peripheral artery disease (PAD).

“Patients with existence-restricting claudication or critical limb ischemia normally have lesions more than 15 cm, so we realize that lesion length is directly proportional to patency. So far, endovascular ways of treating these lengthy lesions haven’t been similar to open bypass surgery,” stated Sean P. Lyden, M.D., professor and chairman from the department of vascular surgery, Sydell and Arnold Miller Family Heart & Vascular Institute at Cleveland Clinic, and national co-principal investigator of DETOUR II.

“The DETOUR procedure is made to treat patients with seriously calcified or lengthy-segment disease. It’s basically a femoropopliteal bypass with polytetrafluoroethylene, but done percutaneously. The DETOUR I trial in Europe shown safety and effectiveness in patients with lesions as lengthy as 44 centimeters long, so we expect to ongoing to review this process using the commencement of DETOUR II.”

DETOUR II is really a prospective, single-arm, global multi-center trial and will also be conducted at as much as 40 sites to allow the gathering of safety and effectiveness data meant for a pre-market approval (PMA) submission towards the Food and drug administration.

Furthermore, to show health economic outcomes, the trial features a prospective economic study made to collect data associated with the expense connected with treating PAD within the study population. An financial aspects core lab may lead the gathering of quality-of-existence outcome measures (collected at baseline, thirty days, six and 12 several weeks), and procedural and follow-up costs, including rehospitalizations, through 24 several weeks.

“We labored carefully using the Food and drug administration, leading physicians and healthcare managers to create an effort that people be prepared to demonstrate the entire worth of this excellent method of treating severe PAD,” stated Richard Ferrari, chairman from the board of company directors at PQ Bypass. “DETOUR II is definitely an exciting milestone within the journey toward creating a potentially transformative future standard of take care of these patients.”

Percutaneous femoropopliteal bypass (the DETOUR procedure) is definitely an entirely new procedure enabled by PQ Bypass’ proprietary DETOUR System, which is composed of the TORUS Stent Graft, DETOUR Crossing Device, and DETOUR Snare. The DETOUR procedure results in a path that comes from the SFA, travels with the femoral vein and leads to the popliteal artery, bypassing the diseased area of the artery.

This path enables TORUS Stent Grafts to become put into a continuing line and consistently re-direct oxygen-wealthy bloodstream round the blockage, restoring bloodstream flow towards the calf and feet from the patient. Unlike existing technologies for example stents and drug-coated balloons, which just produce a funnel with the disease and aren’t created for very lengthy blockages, the DETOUR procedure is really a unique solution made to supply the reliability of open bypass surgery however with a non-invasive approach.

“The DETOUR System includes a truly innovative, intuitive design and also the trial will investigate its benefits in addressing lengthy lesions that aren’t well offered by existing minimally-invasive approaches,” stated Jihad A. Mustapha, M.D., clinical affiliate professor of drugs, Michigan Condition College College of Osteopathic Medicine and national co-principal investigator from the DETOUR II Trial. “We expect to dealing with the DETOUR II Trial clinical sites about this important research.”

Source: Company Pr Release

Interview with Marten Cruz of Microchip Technology Corporation.’s Medical Products Group

Microchip Technology Corporation. is really a provider of microcontroller, mixed-signal, and analog semiconductors that can offer low-risk product at lower total system costs along with a faster time for you to marketplace for a large number of diverse applications. Individuals within the electrical engineering world are extremely acquainted with their PIC microcontrollers, digital signal controllers, along with other microprocessors. However, within the medtech prototyping world, understanding that Microchip includes a special group focused on medical solutions might be less frequent.

Microchip cultivates a top-notch number of Medical Design Partner Specialists, featuring its engineering companies all over the world that offer product and style services to Microchip customers. A number of these design partners are Food and drug administration registered and licensed in quality management standards such as ISO 9001 and ISO 13485, common certifications which are needed for delivery of medical devices to make sure that their safety for their intended purpose, were correctly manufactured, which hardware and software designs for medical devices stick to strict rules.

Medgadget had an opportunity to meet up with some people from the Microchip Medical Products Group following the annual Microchip MASTERs conference, coupled with an chance to interview Marten Cruz, the company Development Manager from the Medical Products Group.

Alice Ferng, Medgadget: Just when was the Medical Products Group team put together and why?

Marten Cruz, Microchip Technology Corporation.: The Medical Products Group was initially put together in 2006 to pay attention to the requirements of medical clients. Microchip is well-recognized for their good support, so we wanted to provide great customer care to medical customers making Food and drug administration Class 1, 2, and three devices, so we’ve been carrying this out for 11 years. A part of achieving the aim of covering all of the bases with customers is creating reference designs. These designs help people thinking about making medical devices to obtain began and to have their designs to promote considerably faster. The overall idea of these reference designs would be that the customers can download the schematics, the code and also the application notes. We lend these demos to the sales pressure and also to select distributors to ensure that customers can make use of the demos for his or her initial prototype designs.

Medgadget: How were the particular reference design demos you presently have were selected to become developed? Exist fields of drugs you’re creating demos for or are intending to target? Are you able to also outline a number of Microchip’s choices associated with these applications?

Mr. Cruz: We target medical customers of any size and also have been very effective within the medical device market. The greatest regions of demand and want are areas for example remote patient monitoring and drug delivery, which we’re feeling play perfectly into our current demos. These demos show applications that measure vital signs, deliver  medication or result in the medical device an IoT device. This assists you to connect the medical device to some smartphone and finally up to and including cloud server.

Healthcare is presently trending, having a growing focus on homecare and personalized medicine, along with the transition of consumer fitness to medical markets. Security therefore is another major problem. Microchip supplies security devices, offers advanced medical device level security and authentication solutions because well. Using the growing interest in devices that meet extreme low power needs, Microchip offers eXtreme Low-Power (XLP) technology PIC® microcontrollers. Furthermore, we provide innovative, safe, and user-friendly low-power touch and input sensing solutions for example products for touch, sliders, closeness, haptics, 3D tracking, and gesture control.

Medgadget: Are you able to give a few examples of medical applications Microchip has labored on in the last decade?

Mr. Cruz: A fast list includes implanted devices (e.g., cardioverter defibrillators, pacemakers, cardiac monitors, gastric bands, neural stimulators), home-use devices (e.g., activity monitors, bloodstream glucose meters, oxygen concentrators, pregnancy testers,  iontophoresis drug delivery, CPAP, cholesterol testers, digital thermometers), portable devices (e.g., electrocardiograph systems, ambulatory EKG recorders, sphygmomanometers, insulin pumps, muscle stimulators, assistive hearing devices, ambulatory electromyographs), along with other devices (e.g., oxygen sensors, automated cell counters, hospital inventory control interfaces, Ultra violet polymerization activators, hospital bed control, operating room tables, light-based surgical instrumentation, endoscopes, dialysis systems).

Medgadget: How competitive is Microchip along with other semiconductor companies within the medical space?

Mr. Cruz: Microchip is among the couple of semiconductor companies that has ongoing to provide focused support for medical clients in excess of 10 years. We provide both commercial and tech support team to medical clients. Furthermore, we stock parts for Food and drug administration Class 3 and EU Class 3 & 4 medical devices. Many people don’t want to find yourself in offering semiconductor parts to those customers, so you want to continue supporting these customers since there exists a lengthy history of doing this already.

Related: The Microchip Medical Products Group very well be at CES 2018 in Vegas the following month. Their booth is going to be found at South Hall 2, #MP 26070. Since conferences are usually by appointment, if you’re interested, you are able to achieve to [email protected] to setup a gathering.

Here’s a relevant video of the example device Microchip offers:

Link: Microchip’s Medical and Fitness Applications Design Center…

Physician.com M&An offer number two provides it with provider directory

Physician.com, a health care provider practice management startup, makes its second M&An offer in 2 years. Its cope with Connect Health will consolidate the companies and merge them under Physician.com’s brand, based on a business news release.  The merger was funded by several investors including Spring Mountain Capital, StartUp Health insurance and Colle Capital, even though the the transaction were not disclosed.

Connect Healthcare stores the information of just one.two million providers and it has 7.5 million unique users. Its hospital partners include UNC Healthcare, UC North Park Health, Brigham & Women’s Hospital, Hurry College Medical Center, UAB Medicine and Emory College.

Andrei Zimiles, Chief executive officer of Physician.com, described within an email the entire Connect Healthcare team (roughly 30 individuals the Atlanta area, all whom concentrate on supporting hospitals and health systems), their clientele of 150 hospitals and health systems, and all sorts of company technology and assets grew to become a part of Physician.com using the deal.

“Connect Healthcare has for a long time had the ‘system of record’ for hospital provider directories. Our solutions align with this particular incredibly mainly because exactly the same data and workflows accustomed to make provider data actionable to be used on the hospital’s own website could be sent through our syndication platform to the partner network which includes Google, Yelp, Bing, Healthgrades, Vitals, YP.com, Wellness.com, yet others. Additionally, the universal online scheduling solution we launched captured has already been integrated using the Connect Doctor directory platform to allow hospitals to show on online scheduling by themselves sites.”

Included in the deal, Noel Coleman, Connect Healthcare president, will join Physician.com as president of Enterprise Solutions, based on a news release. Connect Healthcare’s team works with Physician.com’s enterprise sales and product team. The Enterprise team continuously operate from their headquarters in Atlanta, GA and is anticipated to develop substantially within the several weeks ahead.

This past year, Doctor.com acquired ReferBright, which develops software to assist physicians improve referrals partly by improving their visibility online to draw in more patients for their practices.

Photo: mediaphotos, Getty Images

MedCity ENGAGE, October 23-24 in North Park, concentrates on the most recent strategies and innovations to boost patient engagement, care delivery and company wellness. Use code MCNTAG in order to save $50.